AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03986385
Drug: Capecitabine Oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
Trial: NCT04652323
Drug: Biocompatibility of calcium silicate cements
RxNorm normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.
Trial: NCT00807326
Drug: Probiotic Saccharomyces boulardii 250 mg capsules
RxNorm normalized name: Saccharomyces boulardii Chewable Tablet [Rezyst Probiotic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
Trial: NCT05984251
Drug: CCX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05984251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03885258
Drug: Melatonin Replacement Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (Aché Pharmaceutics, Brazil), 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
Trial: NCT00708149
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: takepron placebo
Trial: NCT00006051
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00951847
Drug: oxcarbazepine 300 mg/5 mL oral suspension
RxNorm normalized name: Oxcarbazepine 300 MG/5 ML Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00528515
Drug: Diprivan (propofol), Astra-Zeneca
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous intravenous infusion with a dose of 3-5 mg/kg/h
Trial: NCT00528515
Drug: Suprane (desflurane), Baxter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
Trial: NCT01722604
Drug: Azopt 1%
RxNorm normalized name: Azopt 1% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azopt 1%, RLD
Trial: NCT00648947
Drug: Plavix® Tablets 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg, single dose fasting
Trial: NCT00467363
Drug: acetylsalicylic-acid (aspirin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81mg of low-dose aspirin plus 400micrograms of folic acid.
Trial: NCT00043394
Drug: Herceptin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
Trial: NCT00043394
Drug: 0.08 mg/kg CpG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
Trial: NCT00043394
Drug: 0.16 mg/kg CpG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
Trial: NCT03999684
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)
Trial: NCT04601792
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
Trial: NCT04601792
Drug: Tested drug minus heat-clearing herbs
RxNorm normalized name: Arctium minus root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
Trial: NCT04032119
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine
Trial: NCT04152096
Drug: Rheosorbilact®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
Trial: NCT04152096
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
Trial: NCT00780494
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 850mg/m2, Orally twice daily days 1-14 every 21 days.
Trial: NCT05514860
Drug: Anti-Arrhythmic Drug Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
Trial: NCT01382797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration
Trial: NCT00362765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00868374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
Trial: NCT02436447
Drug: MTP-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.
Trial: NCT02436447
Drug: MTP-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.
Trial: NCT02436447
Drug: MTP-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment
Trial: NCT03328676
Drug: Placebo oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
Trial: NCT00652288
Drug: Insulin analogs (Lispro and Glargine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs given in single injection
Trial: NCT00725803
Drug: GS-9450 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GS-9450 administered orally once daily
Trial: NCT02453386
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00560443
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,5 mg/kg per os one time
Trial: NCT00927290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 45 mg QD (30 mg QD the first month)
Trial: NCT02272647
Drug: IM Saline Placebo (0.25 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02272647
Drug: IM Estradiol valerate (2.5 mg)
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02272647
Drug: IM Saline Placebo (0.5 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00243386
Drug: Antihemophilic factor, recombinant, manufactured protein-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
Trial: NCT00243386
Drug: Antihemophilic factor, recombinant, manufactured protein-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
Trial: NCT02272647
Drug: IM Estradiol valerate (5.0 mg)
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02272647
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02272647
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (in lieu of Medroxyprogesterone)
Trial: NCT01718496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with advanced COPD on the other study arm will randomly receive Placebo
Trial: NCT02082392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A substance or treatment of no intended therapeutic value in a pill form.
Trial: NCT04213105
Drug: QL1206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection of 60 mg (1ml) only once,on the first day.
Trial: NCT01022242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a physiological sodium chloride solution, which is clear and colourless.
Trial: NCT00545298
Drug: Nitric Oxide - same dose 6 wks
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
Trial: NCT00545298
Drug: Nitric Oxide modified treatment
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
Trial: NCT03218137
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
Trial: NCT00004132
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01471171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
Trial: NCT00525993
Drug: etoricoxib 90mg 14 days
RxNorm normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: each patient in this group will receive 90mg once daily, for the 14 days treatment.
Trial: NCT00525993
Drug: etoricoxib 60mg daily for 14 days
RxNorm normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive 60mg of the drug, daily
Trial: NCT01033825
Drug: AQ Nasal Spray Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AQ Nasal Spray Placebo once daily
Trial: NCT01550146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv. Normal Saline 0.1 ml/kg
Trial: NCT01328951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.
Trial: NCT01393054
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug name: Nigella sativa seed extract in capsule Dosage 300 mg Frequency: twice daily Duration: 4 weeks
Trial: NCT01318434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00074321
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01093963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral; 20-70mg/day
Trial: NCT02043548
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
Trial: NCT00925054
Drug: rAvPAL-PEG 0.003 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1, the planned starting dose levels is 0.003 mg/kg
Trial: NCT00925054
Drug: rAvPAL-PEG 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1, the planned starting dose levels is 0.03 mg/kg
Trial: NCT00925054
Drug: rAvPAL-PEG 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1, the planned starting dose levels is 0.1 mg/kg
Trial: NCT02130739
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.
Trial: NCT01015651
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.
Trial: NCT01015651
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.
Trial: NCT01403818
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01403818
Drug: Mitiglinide calcium hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03985865
Drug: Intraduodenal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
Trial: NCT00099047
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00099047
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00660426
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00665145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04355273
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: heparin with a concentration of 2 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
Trial: NCT04355273
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: heparin with a concentration of 4 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
Trial: NCT04355273
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
Trial: NCT00394810
Drug: Panzem® NCD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suspension, 100 mg/mL, four times daily continuous dosing
Trial: NCT01473953
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
Trial: NCT01802853
Drug: RO6811135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous dose
Trial: NCT00254748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00150826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given in a capsule form once daily for 16 weeks.
Trial: NCT01392677
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
Trial: NCT00966329
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART regimen including 2 NRTI/NtRTIs plus one of the following :~* 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~* or ATV/unboosted (in a regimen without tenofovir)~* or 1 NNRTI (nevirapine or efavirenz).
Trial: NCT03077685
Drug: NanoPac®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
Trial: NCT01677754
Drug: RO4602522
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RO4602522 orally once daily for 12 months.
Trial: NCT01613040
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily oral high doses of RO4917838 for 10 days
Trial: NCT02785120
Drug: TF0023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
Trial: NCT02259881
Drug: Low dose of BIBT 986 CL, per i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02259881
Drug: Medium dose of BIBT 986 CL, per i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02259881
Drug: High dose of BIBT 986 CL, per i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02259881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02125227
Drug: Rosuvastatin, Metformin, YH14755
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT02125227
Drug: YH14755
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT03648658
Drug: Paracetamol 120Mg/5mL Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be treated with paracetamol in therapeutic doses, 15mg/kg/dose every six hour, with a maximum dosage of 1 g x 4 per day, for three consecutive days.
Trial: NCT03331445
Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation
RxNorm normalized name: nitric oxide 0.5 % / nitrogen 99.5 % Gas for Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide 160ppm balance air
Trial: NCT01907334
Drug: Methacholine Chloride
RxNorm normalized name: Methacholine Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
Trial: NCT00276848
Drug: Fludarabine plus Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, plus cyclophosphamide dosed at 250 mg/m2, administered intravenously daily over 30 minutes for 3 days, repeated every 28 days for a maximum of 6 courses
Trial: NCT03707171
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
Trial: NCT05729529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral gel used on tongue
Trial: NCT03970694
Drug: oxaliplatin+capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.
Trial: NCT01032083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
Trial: NCT03483194
Drug: Kalinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
Trial: NCT00934050
Drug: ELND005 (scyllo-inositol)
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks~After 15Dec2009: ELND005 250 mg PO BID for 48 weeks
Trial: NCT00875550
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rescue medication for pain based on UMSS scores